Autoimmune bullous diseases. The spectrum of infectious agent antibodies and review of the literature

Autoimmunity Reviews

Volumn 10, Issue 9, 2011, Pages 527-535

  Sagi, Lior ^a   Baum, Sharon ^a   Agmon Levin, Nancy ^a   Sherer, Yaniv ^a   Katz, Bat Sheva Porat ^b   Barzilai, Ori ^a   Ram, Maya ^a   Bizzaro, Nicola ^d   SanMarco, Marielle ^e   Trau, Henri ^a   Shoenfeld, Yehuda ^a,c  

^a SHEBA MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d Ospedale Civile   (Italy)

^e HÔPITAL DE LA CONCEPTION   (France)

Author keywords

Autoimmunity; Bullous pemphigoid; Cytomegalovirus; Epstein Barr virus; Helicobacter pylori; Hepatitis b virus; Hepatitis c virus; Pemphigus; Toxoplasma gondii; Treponema pallidum

Indexed keywords

ANTIBODY;

ADULT; AGED; AUTOIMMUNE DISEASE; BULLOUS PEMPHIGOID; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; EVIDENCE BASED PRACTICE; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; INFORMATION RETRIEVAL; LUNG BULLA; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PEMPHIGUS; PREVALENCE; REVIEW; SAMPLE; SCREENING; SERUM; TOXOPLASMA GONDII; TREPONEMA PALLIDUM;

ADULT; AGED; ANTIBODIES, BACTERIAL; ANTIBODIES, PROTOZOAN; ANTIBODIES, VIRAL; BACTERIA; FEMALE; HUMANS; MALE; MIDDLE AGED; PEMPHIGOID, BULLOUS; PEMPHIGUS; RETROSPECTIVE STUDIES; TOXOPLASMA; VIRUSES;

EID: 79957905616     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.04.003     Document Type: Review

References (114)

1. Bolognia Jean L., JLJ, Rapini Ronald P. Dermatology 2008, 2 ed.
2. Klaus Wolff L.A.G., Katz Stephen I., Glichrest Barbara A., Paller Amy S., Leffell David J. Fitzpatrick's Dermatology In General Medicine 2008, 7 ed.
3. Beutner E.H., Jordon R.E. Demonstration of Skin Antibodies in Sera of Pemphigus Vulgaris Patients by Indirect Immunofluorescent Staining. Proc Soc Exp Biol Med 1964, 117:505-510.
4. Schiltz J.R., Michel B. Production of epidermal acantholysis in normal human skin in vitro by the IgG fraction from pemphigus serum. J Invest Dermatol 1976, 67:254-260.
5. Anhalt G.J., Labib R.S., Voorhees J.J., Beals T.F., Diaz L.A. Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 1982, 306:1189-1196.
6. Amagai M., Klaus-Kovtun V., Stanley J.R. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 1991, 67:869-877.
7. Mahoney M.G., Wang Z., Rothenberger K., Koch P.J., Amagai M., Stanley J.R. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J Clin Invest 1999, 103:461-468.
8. Amagai M., Koch P.J., Nishikawa T., Stanley J.R. Pemphigus vulgaris antigen (desmoglein 3) is localized in the lower epidermis, the site of blister formation in patients. J Invest Dermatol 1996, 106:351-355.
9. Amagai M., Tsunoda K., Zillikens D., Nagai T., Nishikawa T. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J Am Acad Dermatol 1999, 40:167-170.
10. Ishii K., Amagai M., Ohata Y., Shimizu H., Hashimoto T., Ohya K., et al. Development of pemphigus vulgaris in a patient with pemphigus foliaceus: antidesmoglein antibody profile shift confirmed by enzyme-linked immunosorbent assay. J Am Acad Dermatol 2000, 42:859-861.
11. Vanderlugt C.J., Miller S.D. Epitope spreading. Curr Opin Immunol 1996, 8:831-836.
12. Tron F., Gilbert D., Joly P., Mouquet H., Drouot L., Ayed M.B., et al. Immunogenetics of pemphigus: an update. Autoimmunity 2006, 39:531-539.
13. Langan S.M., Smeeth L., Hubbard R., Fleming K.M., Smith C.J., West J. Bullous pemphigoid and pemphigus vulgaris-incidence and mortality in the UK: population based cohort study. BMJ 2008, 337:a180.
14. Amerian M.L., Ahmed A.R. Pemphigus erythematosus. Senear-Usher syndrome. Int J Dermatol 1985, 24:16-25.
15. Jordon R.E. "An unusual type of pemphigus combining features of lupus erythematosus" by Senear and Usher, June 1926. Commentary: Pemphigus erythematosus, a unique member of the pemphigus group. Arch Dermatol 1982, 118:723-742.
16. Lombardi C., Borges P.C., Chaul A., Sampaio S.A., Rivitti E.A., Friedman H., et al. Environmental risk factors in endemic pemphigus foliaceus (Fogo selvagem). "The Cooperative Group on Fogo Selvagem Research". J Invest Dermatol 1992, 98:847-850.
17. Tajima M, Mitsuhashi Y, Irisawa R, Amagai M, Hashimoto T, Tsuboi R. IgA pemphigus reacting exclusively to desmoglein 3. Eur J Dermatol;20:626-9.
18. Santiago-et-Sanchez-Mateos D., Juarez Martin A., Gonzalez De Arriba A., Delgado Jimenez Y., Fraga J., Hashimoto T., et al. IgG/IgA pemphigus with IgA and IgG antidesmoglein 1 antibodies detected by enzyme-linked immunosorbent assay: presentation of two cases. J Eur Acad Dermatol Venereol 2011, 25:110-112.
19. Billet S.E., Grando S.A., Pittelkow M.R. Paraneoplastic autoimmune multiorgan syndrome: review of the literature and support for a cytotoxic role in pathogenesis. Autoimmunity 2006, 39:617-630.
20. Anhalt G.J. Paraneoplastic pemphigus. J Investig Dermatol Symp Proc 2004, 9:29-33.
21. Li J., Bu D.F., Huang Y.C., Zhu X.J. Role of autoantibodies against the linker subdomains of envoplakin and periplakin in the pathogenesis of paraneoplastic pemphigus. Chin Med J (Engl) 2009, 122:486-495.
22. Sklavounou A., Laskaris G. Paraneoplastic pemphigus: a review. Oral Oncol 1998, 34:437-440.
23. Maldonado F., Pittelkow M.R., Ryu J.H. Constrictive bronchiolitis associated with paraneoplastic autoimmune multi-organ syndrome. Respirology 2009, 14:129-133.
24. Sehgal V.N., Srivastava G. Paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome. Int J Dermatol 2009, 48:162-169.
25. Schmidt E., Zillikens D. Modern diagnosis of autoimmune blistering skin diseases. Autoimmun Rev 2010, 10:84-89.
26. Harman K.E., Albert S., Black M.M. Guidelines for the management of pemphigus vulgaris. Br J Dermatol 2003, 149:926-937.
27. Saha M., Powell A.M., Bhogal B., Black M.M., Groves R.W. Pulsed intravenous cyclophosphamide and methylprednisolone therapy in refractory pemphigus. Br J Dermatol 2010, 162:790-797.
28. Gurcan H.M., Ahmed A.R. Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid. Br J Dermatol 2009, 161:723-731.
29. Ahmed A.R., Dahl M.V. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol 2003, 139:1051-1059.
30. Sagi L., Baum S., Gendelman V., Trau H., Barzilai A. The role of therapeutic plasma exchange in pemphigus vulgaris. J Eur Acad Dermatol Venereol 2011, 25:82-86.
31. Ahmed A.R., Spigelman Z., Cavacini L.A., Posner M.R. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006, 355:1772-1779.
32. Schiavo A.L., Puca R.V., Ruocco V., Ruocco E. Adjuvant drugs in autoimmune bullous diseases, efficacy versus safety: Facts and controversies. Clin Dermatol 2010, 28:337-343.
33. Beissert S., Werfel T., Frieling U., Bohm M., Sticherling M., Stadler R., et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol 2006, 142:1447-1454.
34. Martin L.K., Werth V.P., Villaneuva E.V., Murrell D.F. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol 2011, 64:903-908.
35. Thoma-Uszynski S., Uter W., Schwietzke S., Schuler G., Borradori L., Hertl M. Autoreactive T and B cells from bullous pemphigoid (BP) patients recognize epitopes clustered in distinct regions of BP180 and BP230. J Immunol 2006, 176:2015-2023.
36. Sitaru C., Schmidt E., Petermann S., Munteanu L.S., Brocker E.B., Zillikens D. Autoantibodies to bullous pemphigoid antigen 180 induce dermal-epidermal separation in cryosections of human skin. J Invest Dermatol 2002, 118:664-671.
37. Verraes S., Hornebeck W., Polette M., Borradori L., Bernard P. Respective contribution of neutrophil elastase and matrix metalloproteinase 9 in the degradation of BP180 (type XVII collagen) in human bullous pemphigoid. J Invest Dermatol 2001, 117:1091-1096.
38. Dimson O.G., Giudice G.J., Fu C.L., Van den Bergh F., Warren S.J., Janson M.M., et al. Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid. J Invest Dermatol 2003, 120:784-788.
39. Dresow S.K., Sitaru C., Recke A., Oostingh G.J., Zillikens D., Gibbs B.F. IgE autoantibodies against the intracellular domain of BP180. Br J Dermatol 2009, 160:429-432.
40. Iwata Y., Komura K., Kodera M., Usuda T., Yokoyama Y., Hara T., et al. Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid. Arch Dermatol 2008, 144:41-48.
41. Delgado J.C., Turbay D., Yunis E.J., Yunis J.J., Morton E.D., Bhol K., et al. A common major histocompatibility complex class II allele HLA-DQB1* 0301 is present in clinical variants of pemphigoid. Proc Natl Acad Sci U S A 1996, 93:8569-8571.
42. Ahmed A.R., Maize J.C., Provost T.T. Bullous pemphigoid. Clinical and immunologic follow-up after successful therapy. Arch Dermatol 1977, 113:1043-1046.
43. Hadi S.M., Barnetson R.S., Gawkrodger D.J., Saxena U., Bird P., Merrett T.G. Clinical, histological and immunological studies in 50 patients with bullous pemphigoid. Dermatologica 1988, 176:6-17.
44. Joly P., Benichou J., Lok C., Hellot M.F., Saiag P., Tancrede-Bohin E., et al. Prediction of survival for patients with bullous pemphigoid: a prospective study. Arch Dermatol 2005, 141:691-698.
45. Beutner E.H., Jordon R.E., Chorzelski T.P. The immunopathology of pemphigus and bullous pemphigoid. J Invest Dermatol 1968, 51:63-80.
46. Tsuji-Abe Y., Akiyama M., Yamanaka Y., Kikuchi T., Sato-Matsumura K.C., Shimizu H. Correlation of clinical severity and ELISA indices for the NC16A domain of BP180 measured using BP180 ELISA kit in bullous pemphigoid. J Dermatol Sci 2005, 37:145-149.
47. Joly P., Roujeau J.C., Benichou J., Picard C., Dreno B., Delaporte E., et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002, 346:321-327.
48. Kirtschig G., Middleton P., Bennett C., Murrell D.F., Wojnarowska F., Khumalo N.P. Interventions for bullous pemphigoid. Cochrane Database Syst Rev 2010, CD002292.
49. Semkova K., Black M. Pemphigoid gestationis: current insights into pathogenesis and treatment. Eur J Obstet Gynecol Reprod Biol 2009, 145:138-144.
50. Chi C.C., Wang S.H., Charles-Holmes R., Ambros-Rudolph C., Powell J., Jenkins R., et al. Pemphigoid gestationis: early onset and blister formation are associated with adverse pregnancy outcomes. Br J Dermatol 2009, 160:1222-1228.
51. Lu P.D., Ralston J., Kamino H., Stein J.A. Pemphigoid gestationis. Dermatol Online J 2010, 16:10.
52. Doiron P., Pratt M. Antepartum intravenous immunoglobulin therapy in refractory pemphigoid gestationis: case report and literature review. J Cutan Med Surg 2010, 14:189-192.
53. Daniel E., Thorne J.E. Recent advances in mucous membrane pemphigoid. Curr Opin Ophthalmol 2008, 19:292-297.
54. Boedeker C.C., Termeer C.C., Staats R., Ridder G.J. Cicatricial pemphigoid in the upper aerodigestive tract: diagnosis and management in severe laryngeal stenosis. Ann Otol Rhinol Laryngol 2003, 112:271-275.
55. Tyagi S., Bhol K., Natarajan K., Livir-Rallatos C., Foster C.S., Ahmed A.R. Ocular cicatricial pemphigoid antigen: partial sequence and biochemical characterization. Proc Natl Acad Sci U S A 1996, 93:14714-14719.
56. Smith E.P., Taylor T.B., Meyer L.J., Zone J.J. Identification of a basement membrane zone antigen reactive with circulating IgA antibody in ocular cicatricial pemphigoid. J Invest Dermatol 1993, 101:619-623.
57. Rousselle P., Keene D.R., Ruggiero F., Champliaud M.F., Rest M., Burgeson R.E. Laminin 5 binds the NC-1 domain of type VII collagen. J Cell Biol 1997, 138:719-728.
58. Bruch-Gerharz D., Hertl M., Ruzicka T. Mucous membrane pemphigoid: clinical aspects, immunopathological features and therapy. Eur J Dermatol 2007, 17:191-200.
59. Schmidt E., Herzele K., Schumann H., Wesselmann U., Chimanovitch I., Bruckner-Tuderman L., et al. Linear IgA disease with circulating IgA antibodies against the NC16A domain of BP180. Br J Dermatol 1999, 140:964-966.
60. Vassileva S. Bullous systemic lupus erythematosus. Clin Dermatol 2004, 22:129-138.
61. Ludgate M.W., Greig D.E. Bullous systemic lupus erythematosus responding to dapsone. Australas J Dermatol 2008, 49:91-93.
62. Chan L.S., Lapiere J.C., Chen M., Traczyk T., Mancini A.J., Paller A.S., et al. Bullous systemic lupus erythematosus with autoantibodies recognizing multiple skin basement membrane components, bullous pemphigoid antigen 1, laminin-5, laminin-6, and type VII collagen. Arch Dermatol 1999, 135:569-573.
63. Gammon W.R., Heise E.R., Burke W.A., Fine J.D., Woodley D.T., Briggaman R.A. Increased frequency of HLA-DR2 in patients with autoantibodies to epidermolysis bullosa acquisita antigen: evidence that the expression of autoimmunity to type VII collagen is HLA class II allele associated. J Invest Dermatol 1988, 91:228-232.
64. Ishii N., Hamada T., Dainichi T., Karashima T., Nakama T., Yasumoto S., et al. Epidermolysis bullosa acquisita: what's new?. J Dermatol 2010, 37:220-230.
65. Engineer L., Ahmed A.R. Emerging treatment for epidermolysis bullosa acquisita. J Am Acad Dermatol 2001, 44:818-828.
66. Shoenfeld Y., Gilburd B., Abu-Shakra M., Amital H., Barzilai O., Berkun Y., et al. The mosaic of autoimmunity: genetic factors involved in autoimmune diseases-2008. Isr Med Assoc J 2008, 10:3-7.
67. Shoenfeld Y., Zandman-Goddard G., Stojanovich L., Cutolo M., Amital H., Levy Y., et al. The mosaic of autoimmunity: hormonal and environmental factors involved in autoimmune diseases-2008. Isr Med Assoc J 2008, 10:8-12.
68. Kivity S., Agmon-Levin N., Blank M., Shoenfeld Y. Infections and autoimmunity-friends or foes?. Trends Immunol 2009, 30:409-414.
69. Shoenfeld Y., Selmi C., Zimlichman E., Gershwin M.E. The autoimmunologist: geoepidemiology, a new center of gravity, and prime time for autoimmunity. J Autoimmun 2008, 31:325-330.
70. Goldberg I., Shirazi I., Brenner S. In vitro interferon-gamma release test in patients with drug-induced pemphigus. Isr Med Assoc J 2008, 10:424-427.
71. Bastuji-Garin S., Joly P., Picard-Dahan C., Bernard P., Vaillant L., Pauwels C., et al. Drugs associated with bullous pemphigoid. A case-control study. Arch Dermatol 1996, 132:272-276.
72. Ruocco V., Sacerdoti G. Pemphigus and bullous pemphigoid due to drugs. Int J Dermatol 1991, 30:307-312.
73. Vassileva S. Drug-induced pemphigoid: bullous and cicatricial. Clin Dermatol 1998, 16:379-387.
74. Ahmed A.R., Rosen G.B. Viruses in pemphigus. Int J Dermatol 1989, 28:209-217.
75. Kopel D. Serologic reactions in pemphigus vulgaris; an attempt to detect auto-antibodies or a virus in the blood serum or blister fluid in pemphigus vulgaris. J Invest Dermatol 1954, 22:261-262.
76. Angulo J.J. Attempts to isolate a virus from pemphigus foliaceus cases. AMA Arch Derm Syphilol 1954, 69:472-474.
77. Okano M., Thiele G.M., Davis J.R., Grierson H.L., Purtilo D.T. Epstein-Barr virus and human diseases: recent advances in diagnosis. Clin Microbiol Rev 1988, 1:300-312.
78. Horwitz C.A., Henle W., Henle G., Rudnick H., Latts E. Long-term serological follow-up of patients for Epstein-Barr virus after recovery from infectious mononucleosis. J Infect Dis 1985, 151:1150-1153.
79. Marfatia Y.S., Patel S., Makrandi S., Sharma P. Human immunodeficiency virus and pemphigus vulgaris: an interesting association. Indian J Dermatol Venereol Leprol 2007, 73:354-355.
80. Markitziu A., Pisanty S. Pemphigus vulgaris after infection by Epstein-Barr virus. Int J Dermatol 1993, 32:917-918.
81. Memar O.M., Rady P.L., Goldblum R.M., Tyring S.K. Human herpesvirus-8 DNA sequences in a patient with pemphigus vulgaris, but without HIV infection or Kaposi's sarcoma. J Invest Dermatol 1997, 108:118-119.
82. Splaver A., Silos S., Lowell B., Valenzuela R., Kirsner R.S. Case report: pemphigus vulgaris in a patient infected with HIV. AIDS Patient Care STDS 2000, 14:295-296.
83. Tufano M.A., Baroni A., Buommino E., Ruocco E., Lombardi M.L., Ruocco V. Detection of herpesvirus DNA in peripheral blood mononuclear cells and skin lesions of patients with pemphigus by polymerase chain reaction. Br J Dermatol 1999, 141:1033-1039.
84. Ruocco V., Wolf R., Ruocco E., Baroni A. Viruses in pemphigus: a casual or causal relationship?. Int J Dermatol 1996, 35:782-784.
85. Wang G.Q., Xu H., Wang Y.K., Gao X.H., Zhao Y., He C., et al. Higher prevalence of human herpesvirus 8 DNA sequence and specific IgG antibodies in patients with pemphigus in China. J Am Acad Dermatol 2005, 52:460-467.
86. Barzilai O., Sherer Y., Ram M., Izhaky D., Anaya J.M., Shoenfeld Y. Epstein-Barr virus and cytomegalovirus in autoimmune diseases: are they truly notorious? A preliminary report. Ann N Y Acad Sci 2007, 1108:567-577.
87. Zandman-Goddard G., Berkun Y., Barzilai O., Boaz M., Ram M., Anaya J.M., et al. Neuropsychiatric lupus and infectious triggers. Lupus 2008, 17:380-384.
88. Zandman-Goddard G., Gilburd B., Shovman O., Blank M., Berdichevski S., Langevitz P., et al. The homogeneous multiplexed system-a new method for autoantibody profile in systemic lupus erythematosus. Clin Dev Immunol 2005, 12:107-111.
89. Ooka T., de Turenne-Tessier M., Stolzenberg M.C. Relationship between antibody production to Epstein-Barr virus (EBV) early antigens and various EBV-related diseases. Springer Semin Immunopathol 1991, 13:233-247.
90. Meron M.K., Amital H., Shepshelovich D., Barzilai O., Ram M., Anaya J.M., et al. Infectious Aspects and the Etiopathogenesis of Rheumatoid Arthritis. Clin Rev Allergy Immunol 2010, 38:287-291.
91. Sagi L., Sherer Y., Trau H., Shoenfeld Y. Pemphigus and infectious agents. Autoimmun Rev 2008, 8:33-35.
92. Ichiki Y., He X.S., Shimoda S., Ishibashi H., Keeffe E.B., Rossaro L., et al. T cell immunity in hepatitis B and hepatitis C virus infection: implications for autoimmunity. Autoimmun Rev 2005, 4:82-95.
93. Berkun Y., Mimouni D., Shoenfeld Y. Pemphigus following hepatitis B vaccination-coincidence or causality?. Autoimmunity 2005, 38:117-119.
94. Erbagci Z. Childhood bullous pemphigoid following hepatitis B immunization. J Dermatol 2002, 29:781-785.
95. Fujiwara K., Yokosuka O., Kojima H., Kanda T., Saisho H., Hirasawa H., et al. Importance of adequate immunosuppressive therapy for the recovery of patients with "life-threatening" severe exacerbation of chronic hepatitis B. World J Gastroenterol 2005, 11:1109-1114.
96. Inadomi T., Saito T., Kaneko M., Hashimoto T., Suzuki H. Bullous pemphigoid in an HB virus carrier: interaction between corticosteroids and HB virus. J Dermatol 1997, 24:179-183.
97. Merida C., Martinez-Escribano J.A., Frias J.F., Sanchez-Pedreno P., Corbalan R. Bullous pemphigoid in an infant after vaccination. Actas Dermosifiliogr 2005, 96:255-257.
98. Ravel G., Christ M., Horand F., Descotes J. Autoimmunity, environmental exposure and vaccination: is there a link?. Toxicology 2004, 196:211-216.
99. Maynard J.E. Hepatitis B: global importance and need for control. Vaccine 1990, (8 Suppl.):S18-S20. discussion S1-3.
100. Yang C.H., Wu T.S., Chiu C.T. Chronic hepatitis B reactivation: a word of caution regarding the use of systemic glucocorticosteroid therapy. Br J Dermatol 2007, 157:587-590.
101. Ram M., Anaya J.M., Barzilai O., Izhaky D., Porat Katz B.S., Blank M., et al. The putative protective role of hepatitis B virus (HBV) infection from autoimmune disorders. Autoimmun Rev 2008, 7:621-625.
102. Plot L., Amital H., Barzilai O., Ram M., Nicola B., Shoenfeld Y. Infections may have a protective role in the etiopathogenesis of celiac disease. Ann N Y Acad Sci 2009, 1173:670-674.
103. Daoud M.S., Gibson L.E., Daoud S., el-Azhary R.A. Chronic hepatitis C and skin diseases: a review. Mayo Clin Proc 1995, 70:559-564.
104. Pakula A.S., Garden J.M., Roth S.I. Cryoglobulinemia and cutaneous leukocytoclastic vasculitis associated with hepatitis C virus infection. J Am Acad Dermatol 1993, 28:850-853.
105. Agmon-Levin N., Ram M., Barzilai O., Porat-Katz B.S., Parikman R., Selmi C., et al. Prevalence of hepatitis C serum antibody in autoimmune diseases. J Autoimmun 2009, 32:261-266.
106. Niizeki H., Inamoto N., Nakamura K., Tsuchimoto K., Hashimoto T., Nishikawa T. A case of pemphigus foliaceus after interferon alpha-2a therapy. Dermatology 1994, 189(Suppl. 1):129-130.
107. Blaser M.J., Chen Y., Reibman J. Does Helicobacter pylori protect against asthma and allergy?. Gut 2008, 57:561-567.
108. Lidar M., Langevitz P., Barzilai O., Ram M., Porat-Katz B.S., Bizzaro N., et al. Infectious serologies and autoantibodies in inflammatory bowel disease: insinuations at a true pathogenic role. Ann N Y Acad Sci 2009, 1173:640-648.
109. Drago F., Nozza P., Casazza S., Brusati C., Bandelloni R., Rebora A. Human herpesviruses in bullous pemphigoid lesions. Br J Dermatol 2005, 152:375-376.
110. Ruocco V., Rossi A., Satriano R.A., Sacerdoti G., Astarita C., Pisani M. Pemphigus foliaceus in a haemophilic child: cytomegalovirus induction?. Acta Derm Venereol 1982, 62:534-537.
111. Berggren M.A., Heinlen L., Isaksson A., Nystrom U., Ricksten A. EBNA1 expression in a lung transplant recipient with hypocomplementemic urticarial vasculitis syndrome. J Med Virol 2007, 79:963-969.
112. Evans A.S. E.B. virus antibody in systemic lupus erythematosus. Lancet 1971, 1:1023-1024.
113. Pender M.P. Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol 2003, 24:584-588.
114. Sun A., Chang J.G., Chu C.T., Liu B.Y., Yuan J.H., Chiang C.P. Preliminary evidence for an association of Epstein-Barr virus with pre-ulcerative oral lesions in patients with recurrent aphthous ulcers or Behcet's disease. J Oral Pathol Med 1998, 27:168-175.